Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a daily probiotic capsule tame irritable bowel syndrome?

NCT ID NCT06687720

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial tests whether an oral probiotic supplement called MetBroma can safely reduce symptoms of irritable bowel syndrome (IBS) and improve quality of life. Adults aged 18 to 60 with an IBS diagnosis will take the probiotic capsule twice a day, and researchers will track changes in symptoms, lifestyle impact, and blood markers like protein levels. The study is small and early-stage, so it aims to gather initial evidence on whether this approach is worth pursuing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MetBroma, an oral probiotic supplement taken as a slow-release capsule twice daily
What this could lead to
If it works, this probiotic could offer a simple, drug-free way to manage IBS symptoms and improve daily life for people with the condition.
What could go wrong
This is a very small, early-stage study with only 18 participants, so results may not apply broadly. Probiotics can also cause mild digestive upset in some people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

18 people

The number who actually took part.

Started

Nov 2024

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The subject is an adult male or female aged between 18 to 60 years old. 2. Clinically diagnosed with irritable bowel syndrome (IBS) based on Rome IV criteria: Abdominal pain at least 4 days per month - over at least 2 months - associated with one or more of the following: i. Related to defecation ii. A change in frequency of stool iii. A change in form (appearance) of stool iv. After appropriate evaluation, the symptoms cannot be fully explained by another medical condition 3. The subject is having refrigerator at their home for storage of test treatment. 4. The subject is willing to provide written informed consent, comply with the study procedures, and be present for all the visits. 5. The subject is willing to abstain from using any other treatments for irritable bowel syndrome during the study period, unless for a medical urgency. 6. The subject is in a stable medical condition, not requiring immediate intervention or hospitalization. 7. If the subject is female, she is willing to use a highly effective method of contraception throughout the clinical investigation. i. Females of childbearing potential must practice and maintain an established method of birth control (e.g., IUD, hormonal implant device/injection, birth control pills, diaphragm, condoms with spermicide, partner vasectomy, or abstinence). ii. Non-childbearing potential females who are surgically sterile, post-menopausal for at least 1 year, or have had a tubal ligation, must have been using hormonal contraception for at least 6 months and agree to continue using the same contraception for the study duration. Exclusion Criteria: 1. The subject has a history of diagnosis of either hypertension, diabetes, or liver disease. 2. The subject has any other significant medical condition that could interfere with the study or pose a risk to the participant. 3. The subject has used medications that could influence the study outcomes, such as antibiotics, immunosuppressive drugs, and probiotics or prebiotics supplements within the last 4 weeks. 4. The subject works in frequent night shifts (working night shifts at least 3 times per week), and refuses to change the lifestyle. 5. The subject has a history of alcohol abuse. 6. The subject is either pregnant, lactating, or plans on conceiving during the course of the study. 7. The subject has participated in other clinical studies or received any investigational agent in the previous 30 days. 8. The subject has other significant gastrointestinal diseases (e.g., Crohn's disease, ulcerative colitis, celiac disease). 9. The subject has any condition that, in the investigator's judgment, would compromise the subject's safety or study integrity. 10. The subject has abnormal baseline Haemoglobin (Hb), Complete Blood Count (CBC), Urine Routine/Microscopy (R/M), or Stool Routine/Microscopy (R/M) results that suggest a different pathology than irritable bowel syndrome.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Irritable bowel syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NovoBliss Research Pvt Ltd

    Ahmedabad, Gujarat, 382481, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.